PLSE
SellHot AirPulse Biosciences, Inc. · Healthcare · United States · $3.4B · Avg Vol: $33M/d
Hot Air: Rising on momentum alone: weak business, rich price.
ABOUT PULSE BIOSCIENCES, INC.
Read
Pulse Biosciences is a novel medical technology company pioneering the development of its proprietary Nano-Pulse Stimulation (NPS) technology for cellular tissue clearance. The company's CellFX system delivers nanosecond electrical pulses to non-thermally clear targeted cells while sparing surrounding non-cellular tissue. Its competitive moat is anchored by a robust intellectual property portfolio and a unique, high-margin consumable business model in dermatology and other surgical applications.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.7M | 0 | 0 | 0.3M | -20.6% | 1.2M | 2.0M | 7.1M | 351.0% |
| EPS | -1.69 | -0.85 | -0.92 | -1.08 | — | -1.17 | -1.11 | -1.15 | — |
| Shares | 37.9M | 56.1M | 65.9M | 67.8M | +79.2% | 71.3M | — | — | — |
| Debt | 76.0M | 9.1M | 8.9M | 7.5M | -53.7% | 6.8M | — | — | — |
| Equity | -2.2M | 44.4M | 114.9M | 80.7M | 34.8% | — | — | — | — |
| Op CF | -47.0M | -33.0M | -36.3M | -54.1M | — | -61.1M | — | — | — |
| Inv CF | -0.4M | -0.1M | -0.1M | -0.3M | — | — | — | — | — |
| Fin CF | 79.9M | 16.4M | 110.1M | 17.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PLSE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PLSE | Pulse Biosciences, Inc.(you) | $3.4B | 22 | Sell |
| WRBY | Warby Parker Inc. | $3.1B | 34 | Sell |
| KMTS | Kestra Medical Technologies, Ltd. | $1.5B | 26 | Sell |
| MMED | MiniMed Group, Inc. | $5.7B | 40 | Hold |
| BLFS | BioLife Solutions, Inc. | $1.8B | 50 | Hold |
| AZTA | Azenta, Inc. | $1.4B | 46 | Hold |
| LMAT | LeMaitre Vascular, Inc. | $1.8B | 53 | Hold |
| XRAY | DENTSPLY SIRONA Inc. | $2.2B | 58 | Hold |
| ICUI | ICU Medical, Inc. | $4.4B | 63 | Hold |
| ATRC | AtriCure, Inc. | $2.5B | 64 | Hold |
Peer medians: ROE -30.9% · P/E 25.1x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.